Immunology of breast cancer / edited by Wei-Zen Wei and Diana M. Lopez.

Colaborador(es):

Tipo de material: Texto

TextoDetalles de publicación: Holanda : IOS Press, 2004Descripción: 153 p. ; 26 cmISBN:

1586034944
9781586034948

ISSN:

0888-6008

Tema(s):

Clasificación LoC:

QR181 .I4 2004

Recursos en línea:

Contenidos:

Introduction / Wei-Zen Wei.-- 1. Peptide-based vaccines in breast Cancer / M.L. Disis, L.G. Salazar and K.L. Knutson.-- 2. Augmenting the potency of breast cancer vaccines: combined modality immunotherapy / L.A. Emens, R.T. Reilly and E.M. Jaffee.-- 3. Her2/neu as a paradigm of a tumor-specific target for therapy / A. Choudhury and R. Kiessling.-- 4. Immunobiology of her-2/neu transgenic. mice / T. Pannellini, G. Forni and P. Musiani.-- 5. From breast cancer immunobiology to her-2 DNA vaccine and autoimmune sequelae / F. Miller, R.F. Jones, J. Jacob, Y.M. Kong and W.-Z. Wei.-- 6. Therapeutic efficacy of muc1-specific cytotoxic t. lymphocytes and CD 137 CO-stimulation / in a Spontaneous Breast Cancer Model P. Mukherjee, T.L. Tinder, G.D. Basu, L.B. Pathangey L. Chen and S.J. Gendler.-- 7. Dendritic cell- based therapeutics for breast cancer / S.A. Pilon-Thomas, M.E. Verhaegen and J.J. Mulé.-- 8. Glycoprotein Tumor Antigens for Immunotherapy of Breast Cancer / A.M. Vlad and O.J. Finn.-- 9. DNA Vaccines Suppress Angiogenesis and Protect Against Growth of Breast Cancer Metastases / N. Mizutani, Y. Luo, M. Mizutani, R.A. Reisfeld and R. Xiang.-- 10. Immune Tolerance in Breast Cancer / F. Cheng, D. Gabrilovich and E. M. Sotomayor.-- 11. HLA Antigen Changes in Malignant Tumors of Mammary Epithelial Origin: Molecular Mechanisms and Clinical Implications / M. Campoli, C.-C. Chang, S.A. Oldford, A.D. Edgecombe, S. Drover and S. Ferrone.-- 12. Antagonists of Tumor-Specific Immunity: Tumor-Induced Immune Suppression and Host Genes that Co-opt the Anti-Tumor Immune Response / S. Ostrand-Rosenberg, P. Sinha, E.A. Danna, S. Miller, C. Davis and S.K. Dissanayake.-- 13.The Role of Chemokines in the Biology and Therapy of Breast Cancer / T.C. Walser and A.M. Fulton.-- 14. T Cell-Derived Matrix Metalloproteinase-9 in Breast Cancer: Friend or Foe? / J.L. Owen, V. Iragavarapu-Charyulu and D.M. Lopez.

Alcance y contenido: In this issue, exciting new directions are outlined by fourteen groups of investigators working on critical areas in 'Breast Cancer Immunology'. In the clinic, patients are responding to Her-2 peptides or GM-CSF transfected tumor cell vaccines. Futhermore, tumors under vaccine induced immune attack can prime the host to additional antigens. Selected chemotherapeutic agents are used to further vaccine efficacy. These promising results highlight the value of breast cancer immunotherapy. Although the clinical progress is exciting, significant challenges remain. Many tumor-associated antigens are self-antigens and vigorous measures will be required to induce consistent and sustained anti-tumor immunity. There is a pressing need for new immunotherapy targets. In this issue, the better-characterized glycoprotein antigens and novel molecules in angiogenesis are examined as new targets of breast cancer vaccines or immunotherapy. Continued effort in new antigen identification will be critical to cancer control. Finally, a reality check is warranted. Most breast cancer cells are still elusive to immune intervention. The mechanisms of such evasion are under intense investigation and much progress has been made. Alteration in antigen processing machinery is a major route of tumor evasion.

Etiquetas de esta biblioteca: No hay etiquetas de esta biblioteca para este título. Ingresar para agregar etiquetas.

Existencias ( 1 )
Notas de título ( 3 )

Existencias
Tipo de ítem	Biblioteca actual	Colección	Signatura topográfica	Estado	Notas	Fecha de vencimiento	Código de barras
01-Préstamo Interno (Libros)	Biblioteca Magna	Acervo General	QR181 .I4 2004	Disponible	Préstamo interno (etiqueta naranja)		085925

Introduction / Wei-Zen Wei.--
1. Peptide-based vaccines in breast Cancer / M.L. Disis, L.G. Salazar and K.L. Knutson.--
2. Augmenting the potency of breast cancer vaccines: combined modality immunotherapy / L.A. Emens, R.T. Reilly and E.M. Jaffee.--
3. Her2/neu as a paradigm of a tumor-specific target for therapy / A. Choudhury and R. Kiessling.--
4. Immunobiology of her-2/neu transgenic. mice / T. Pannellini, G. Forni and P. Musiani.--
5. From breast cancer immunobiology to her-2 DNA vaccine and autoimmune sequelae / F. Miller, R.F. Jones, J. Jacob, Y.M. Kong and W.-Z. Wei.--
6. Therapeutic efficacy of muc1-specific cytotoxic t. lymphocytes and CD 137 CO-stimulation / in a Spontaneous Breast Cancer Model P. Mukherjee, T.L. Tinder, G.D. Basu, L.B. Pathangey L. Chen and S.J. Gendler.--
7. Dendritic cell- based therapeutics for breast cancer / S.A. Pilon-Thomas, M.E. Verhaegen and J.J. Mulé.--
8. Glycoprotein Tumor Antigens for Immunotherapy of Breast Cancer / A.M. Vlad and O.J. Finn.--
9. DNA Vaccines Suppress Angiogenesis and Protect Against Growth of Breast Cancer Metastases / N. Mizutani, Y. Luo, M. Mizutani, R.A. Reisfeld and R. Xiang.--
10. Immune Tolerance in Breast Cancer / F. Cheng, D. Gabrilovich and E. M. Sotomayor.--
11. HLA Antigen Changes in Malignant Tumors of Mammary Epithelial Origin: Molecular Mechanisms and Clinical Implications / M. Campoli, C.-C. Chang, S.A. Oldford, A.D. Edgecombe, S. Drover and S. Ferrone.--
12. Antagonists of Tumor-Specific Immunity: Tumor-Induced Immune Suppression and Host Genes that Co-opt the Anti-Tumor Immune Response / S. Ostrand-Rosenberg, P. Sinha, E.A. Danna, S. Miller, C. Davis and S.K. Dissanayake.--
13.The Role of Chemokines in the Biology and Therapy of Breast Cancer / T.C. Walser and A.M. Fulton.--
14. T Cell-Derived Matrix Metalloproteinase-9 in Breast Cancer: Friend or Foe? / J.L. Owen, V. Iragavarapu-Charyulu and D.M. Lopez.

In this issue, exciting new directions are outlined by fourteen groups of investigators working on critical areas in 'Breast Cancer Immunology'. In the clinic, patients are responding to Her-2 peptides or GM-CSF transfected tumor cell vaccines. Futhermore, tumors under vaccine induced immune attack can prime the host to additional antigens. Selected chemotherapeutic agents are used to further vaccine efficacy. These promising results highlight the value of breast cancer immunotherapy. Although the clinical progress is exciting, significant challenges remain. Many tumor-associated antigens are self-antigens and vigorous measures will be required to induce consistent and sustained anti-tumor immunity. There is a pressing need for new immunotherapy targets. In this issue, the better-characterized glycoprotein antigens and novel molecules in angiogenesis are examined as new targets of breast cancer vaccines or immunotherapy. Continued effort in new antigen identification will be critical to cancer control. Finally, a reality check is warranted. Most breast cancer cells are still elusive to immune intervention. The mechanisms of such evasion are under intense investigation and much progress has been made. Alteration in antigen processing machinery is a major route of tumor evasion.

Área de Ciencias de la Salud